Posts Tagged ‘Dry Eye’
Mimetogen
Presenter: Garth Cumberlidge Garth Cumberlidge has served as the Company’s President, CEO and member of the Board of Directors since September 2005. Dr. Cumberlidge has over 25 years’ experience in the research products, diagnostics and healthcare industries. View Full Profile
Read MoreRPS
Presenter: Robert P. Sambursky, MD Robert Sambursky, MD is CEO, and President of RPS Diagnostics (RPS®), an innovative biotechnology company with a proprietary point-of-care diagnostic testing platform to rapidly and accurately diagnose a variety of infectious diseases and inflammatory conditions. View Full Profile
Read MoreTearScience
Presenter: Tim Willis Mr. Willis has more than 35 years of medical device industry experience. Tim is an entrepreneur and inventor and has been responsible for the development and launch of 50+ products that today represent over a half billion dollars in annual sales. View Full Profile
Read MoreTearLab
Presenter: Elias Vamvakas Mr Vamvakas is the Chairman and CEO of TearLab Corporation. Prior to TearLab, Mr. Vamvakas co-founded TLCVision (NASDAQ/TLCV, TSX/TLC) in 1993 where he served as President and CEO until 2003. View Full Profile
Read MoreDry Eye Market Overview
Edward J Holland, MD explains where we are and where we might be going with Dry Eye, stressing the significance of the Dry Eye problem and the opportunity it presents to the industry. Presenter: Edward Holland, MD Dr. Holland is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Clinical Ophthalmology at…
Read MoreDry Eye Challenges & Opportunities
Up to 60% of ophthalmologist patients have some form of ocular surface disease impacting over 60 million Americans. A Gallop poll of dry eye sufferers shows: 72% of patients use an artificial tear. 82% wish that there was something more effective to treat dry eye. 97% say that their dry eye condition is frustrating. The…
Read MoreNovaliq Clears the Obstacles in Ocular Track Delivery
Bernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity to resolve these issues by dissolving poorly soluble tracks, with low viscosity and surface tension. Presenter: Bernhard Günther Bernhard Günther joined Novaliq as CEO in January 2007. He has more…
Read More